Eyenovia, Inc. (EYEN)

NASDAQ: EYEN · IEX Real-Time Price · USD
2.02
0.00 (0.00%)
May 20, 2022 4:30 PM EDT - Market closed
Market Cap67.81M
Revenue (ttm)12.00M
Net Income (ttm)-14.77M
Shares Out33.57M
EPS (ttm)-0.54
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume46,203
Open2.03
Previous Close2.02
Day's Range1.98 - 2.06
52-Week Range1.83 - 6.63
Beta2.08
AnalystsBuy
Price Target14.96 (+640.6%)
Earnings DateMay 12, 2022

About EYEN

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydria...

IndustryPharmaceuticals
IPO DateJan 25, 2018
Employees43
Stock ExchangeNASDAQ
Ticker SymbolEYEN
Full Company Profile

Financial Performance

In 2021, Eyenovia's revenue was $14.00 million, an increase of 600.00% compared to the previous year's $2.00 million. Losses were -$12.78 million, -35.36% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for EYEN stock is "Buy." The 12-month stock price forecast is 14.96, which is an increase of 640.59% from the latest price.

Price Target
$14.96
(640.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Eyenovia Reports First Quarter 2022 Financial Results

Mydcombi™ NDA resubmission on track for Q3 2022

1 week ago - GlobeNewsWire

Eyenovia to Report First Quarter 2022 Results on Thursday, May 12

Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day

2 weeks ago - GlobeNewsWire

Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refra...

Presentation to review historic issues related to glaucoma therapies and how these may be addressed through the use of Optejet® technology Presentation to review historic issues related to glaucoma ther...

1 month ago - GlobeNewsWire

Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose array print (MAP™) spray using the company's proprietary OpteJet® dispenser Results of “SPEED” study confirm ...

1 month ago - GlobeNewsWire

Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results

Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022

1 month ago - GlobeNewsWire

Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28

Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day

2 months ago - GlobeNewsWire

Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Ce...

Study conducted with Tufts Medical Center represents a breakthrough showing that Microdose Array Print (MAP™) technology can provide similar benefits of non-preserved medications Study conducted with Tu...

2 months ago - GlobeNewsWire

Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master ...

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today anno...

2 months ago - GlobeNewsWire

8 Penny Stocks To Buy Now According To Insiders In 2022

Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 months ago - PennyStocks

Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission

No additional clinical work required; NDA resubmission anticipated in Q3 2022 No additional clinical work required; NDA resubmission anticipated in Q3 2022

3 months ago - GlobeNewsWire

Eyenovia Announces Changes to Board of Directors

NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today annou...

3 months ago - GlobeNewsWire

Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates

Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of 11.54% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Eyenovia Reports Third Quarter 2021 Financial Results

On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022

6 months ago - GlobeNewsWire

Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting

Discussion to Include Future Potential Treatment Options, Including MicroPine (atropine ophthalmic spray), for reduction of myopia progression in pediatrics Discussion to Include Future Potential Treatm...

6 months ago - GlobeNewsWire

CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released ...

6 months ago - GlobeNewsWire

Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11

Company to host an investor conference call and webcast at 5:00pm ET on that day Company to host an investor conference call and webcast at 5:00pm ET on that day

6 months ago - GlobeNewsWire

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia

Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Eyenovia, Inc. - EYEN

NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN).  Such investors are advised to contact...

6 months ago - PRNewsWire

Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA

Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers

6 months ago - GlobeNewsWire

Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?

Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.

7 months ago - Zacks Investment Research

5 Best Penny Stocks To Buy Right Now According To Insiders

5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:ALTOCOCPHOFVSCPS
8 months ago - PennyStocks

Eyenovia Reports Second Quarter 2021 Financial Results

Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia

9 months ago - GlobeNewsWire

Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021

NEW YORK & LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- #ASCRS2021--Eyenovia will participate in a July 22 Eyecelerator@ASCRS panel, entitled, “Presbyopia: Everybody gets it... but can it be fixed?” 

10 months ago - Business Wire

Eyenovia to Participate in Two Upcoming Investor Conferences

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array pri...

10 months ago - GlobeNewsWire

Eyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia Study

Eyenovia Inc (NASDAQ: EYEN) has announced topline data from its VISION-1 Phase 3 study evaluating MicroLine, for the temporary improvement of near vision in adults with presbyopia. The results will be p...

11 months ago - Benzinga